Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Effector Therapeutics Inc
EFTRCurrent price
0.0004 USD
+0.0001 USD (+33.33%)
Last closed
0.0004 USD
Company
effector.com
ISIN
US28202V1089
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 882 USD
Yield for 12 month
-100.00 %
1Y
3Y
5Y
10Y
15Y
EFTR
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California. Address: 142 North Cedros Avenue, Solana Beach, CA, United States, 92075
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+3 553 000 USD
Current Quarter
–
Last Quarter
+162 000 USD
Current Year
-22 919 000 USD
Last Year
+3 500 000 USD
Current Quarter
-28 000 USD
Last Quarter
+132 000 USD
Key Figures EFTR
1 year
3 years
5 years
10 years
EBITDA
-32 593 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-83.33 %
PEG Ratio
–
Return On Equity TTM
-946.56 %
Wall Street Target Price
10 USD
Revenue TTM
675 000 USD
Book Value
0.21 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
117 %
Dividend Yield
–
Gross Profit TTM
-19 760 000 USD
Earnings per share
-12.57 USD
Diluted Eps TTM
-12.57 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics EFTR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EFTR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:25
Payout Ratio
–
Last Split Date
12.01.2024
Dividend Date
–
Stock Valuation EFTR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
69.6486
Enterprise Value EBITDA
-0.4074
Price Book MRQ
0.0023
Financials EFTR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators EFTR
For 52 weeks
0.0001 USD
17.9 USD
50 Day MA
0.029 USD
Shares Short Prior Month
94 713
200 Day MA
3.55 USD
Short Ratio
0.97
Shares Short
91 617
Short Percent
1.97 %
BeatStart